08/14/2026 | Companies

AI Agents, AI Drug Discovery, AI for Science, AI-Driven R&D, AI-Native Infrastructure, Antibody Discovery, Antibody Drug Development, Artificial Intelligence, AuraIDE, Aureka Biotechnologies, Biological AI, Biological Foundation Models, Biological Function Prediction, Biological World Model, Biologics, Biomolecular Modeling, Biotechnology, Biotechnology Investment, Closed-Loop AI, Computational Biology, De Novo Molecular Design, Drug Development, Drug Discovery, Drug Discovery Platforms, Dual-Target Antibodies, Foundation Models, Generative AI, Generative Antibody Design, GPCR Drug Discovery, Granite Asia, High-Throughput Screening, HighLight Capital, Lab-in-the-Loop, Life Sciences, Machine Learning, Molecular Design, MPCi, NRL Capital, OpenDDE, Pharmaceutical Innovation, Pharmaceutical R&D, Protein Engineering, Protein Structure Prediction, Series B Financing, Single-Cell Screening, TechBio, TechBio Investment, Venture Financing, Wet-Lab Automation